The investigators analysed 235 stored DNA extracts from symptomatic individuals. They derived NG-MAST sequence types for 200 of those 235 specimens (85.1%), indicating a high success rate for molecular typing directly from clinical material. Sequence types were diverse across the cohort; ST21253 was the most frequently observed, present in 26 isolates. The cohort composition and specific sampling frame beyond symptomatic status were those reported by the authors; the source did not report additional demographic breakdowns in the abstract.
The study team applied real-time PCR directly to specimen DNA to detect quinolone resistance-associated mutations (RAMs) in parC and gyrA, plus macrolide RAMs in the 23S rRNA gene. At least one gyrA or parC mutation was identified by PCR in 110 out of 193 specimens tested (57.0%). The 23S rRNA C2611T mutation was detected in a single isolate; no A2059G mutations were reported. The authors included targeted marker lists in their methods as described in the source; details of primer sequences or PCR cycling conditions are not reported in the abstract.
Investigators compared PCR results with WGS from paired cultured isolates when available. Agreement metrics varied by target: for parC, positive agreement with WGS was 81.2% and negative agreement 100%. For gyrA, positive agreement reached 97.0% and negative agreement 95.8%. These figures indicate strong concordance for gyrA detection by PCR relative to WGS, while parC detection showed lower positive agreement but perfect negative agreement in the reported comparisons.
Phenotypic susceptibility data from paired isolates were used to evaluate the predictive value of the targeted markers. Among 65 ciprofloxacin-resistant isolates, resistance-associated mutations were detected in 60 (92.3%) by real-time PCR and in 61 (93.8%) by WGS. Four ciprofloxacin-resistant isolates lacked a detected RAM by either molecular method. The single 23S rRNA C2611T mutation detected corresponded to an isolate with an azithromycin minimum inhibitory concentration of 8 mg/L. No A2059G mutations were observed in the tested specimens. The study team therefore reported that the targeted molecular markers did not fully predict ciprofloxacin susceptibility for all resistant isolates.
The authors framed this work against constrained culture capacity for gonococcal surveillance in the region. They reported that molecular typing and targeted PCR can be applied directly to clinical specimens, yielding high typing success (85.1% for NG-MAST) and substantial detection of quinolone RAMs. Real-time PCR agreed well with WGS for the assessed markers, particularly gyrA, supporting use of molecular tools where culture is limited. At the same time, the presence of resistant isolates without detectable targeted RAMs suggests that reliance on a restricted set of molecular markers could miss some resistance mechanisms, so the investigators advocated complementary molecular and phenotypic approaches in surveillance workflows.
The authors noted limitations implicit in the reported results: targeted PCR markers did not fully predict ciprofloxacin susceptibility, and the abstract indicates surveillance remains constrained by limited culture capacity. The source did not provide full methodological parameters (for example, PCR primer sequences and detailed sample demographics) within the abstract; those details may appear in the full manuscript or supplementary material. All data produced in the study are available upon reasonable request to the authors, according to the report. Readers should also note this work is posted as a medRxiv preprint and has not been peer-reviewed; the authors explicitly stated that it should not be used to guide clinical practice. The Research Ethics Committee of the Faculty of Health Sciences, University of Pretoria, provided ethical approval (reference number: 42/2024), as documented by the authors in the source.
The study ends with concrete unanswered questions documented in the abstract: which additional molecular markers or mechanisms account for the ciprofloxacin-resistant isolates lacking detected RAMs, and how best to integrate molecular and phenotypic surveillance where culture capacity is limited. The source did not list further regulatory milestones or timelines.